Unblocked Future: Why Gene Patents Won’t Hinder Whole-Genome Sequencing and Personalized Medicine
31 Pages Posted: 23 Aug 2011 Last revised: 3 Apr 2016
Date Written: August 7, 2011
Whole-genome sequencing has been hailed as the crucial next step in personalized medicine. It has also been described as likely violating hundreds if not thousands of pre-existing patents on individual genes. These claims of patent infringement, however, are usually made without detailed analysis. Instead of stating that infringement definitely occurs, or in what circumstances, the discussion of whole-genome sequencing mentions that some claims may be typically infringed, but some may be invalid, and leaves the matter there. This paper seeks to provide a detailed analysis of the ways that whole-genome sequencing may infringe extant gene patents, focusing on the common basic structure of most such patents. In particular, the sequencing step itself may infringe the composition of matter claims of isolated DNA molecules in only a very few gene patents, with novel nanopore sequencing technology appearing to bypass infringement altogether. Gene patents often also include methods claims for comparing the personal sequence with a reference sequence for diagnostic purposes; these claims are much more likely infringed by any plausible whole-genome sequencing effort, but appear to fall into a two-class trap where comparison-only methods claims are vulnerable to § 101 patentable subject matter challenges and determination-and-comparison methods can be relatively easily avoided by having different entities perform the sequencing and analysis steps. The paper concludes with a brief analysis of policy considerations for whole-genome sequencing and suggestions for moving forward.
Keywords: gene patents, whole-genome sequencing, personalized medicine
JEL Classification: O33
Suggested Citation: Suggested Citation
European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' Brca Patent Controversy